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Abstract: In recent years, there has been an upsurge in cases of drug-resistant TB, and
strains of TB resistant to all forms of treatment have begun to emerge; the highest level of
resistance is classified as extensively drug-resistant tuberculosis (XDR-TB). There is an
urgent need to prevent poor outcomes (death/default/failed treatment) of XDR-TB, and
knowing the risk factors can inform such efforts. The objective of this scoping review was
to therefore identify risk factors for poor outcomes among XDR-TB patients. We searched
three scientific databases, PubMed, Scopus, and ProQuest, and identified 25 articles that
examined relevant risk factors. Across the included studies, the proportion of patients with
poor outcomes ranged from 8.6 to 88.7%. We found that the most commonly reported risk
factor for patients with XDR-TB developing poor outcomes was having a history of TB.
Other risk factors were human immunodeficiency virus (HIV), a history of incarceration, low
body mass, being a smoker, alcohol use, unemployment, being male, and being middle-aged.
Knowledge and understanding of the risk factors associated with poor outcomes of XDR-TB
can help policy makers and organizations in the process of designing and implementing
effective programs.
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An estimated 1.7 billion people are currently infected with Mycobacterium
tuberculosis,1 the causative agent of tuberculosis (TB). TB was the leading cause
of mortality from a single pathogen in 2018, with the bacterium being the attributed
caused of approximately 1.5 million deaths worldwide.2
Successful treatment of TB is crucial to both curing the individual patient and
reducing the transmission of Mycobacterium tuberculosis in the community. Firstline treatment includes combination of chemotherapy, such as isoniazid, rifampicin,
pyrazinamide, and ethambutol.3 However, A major issue is the widespread pre
valence of drug-resistant TB (DR-TB). At least 5% of all global cases of TB have
some form of drug-resistance, that is, resistance to at least one first-line anti-TB
drug.4 Multi-drug resistant TB (MDR-TB) is defined as resistance to at least two
first-line anti-TB drugs, isoniazid and rifampin,2 and extensively drug-resistant TB
(XDR-TB) is defined as resistance to isoniazid and rifampin, as well as any
fluoroquinolone and any Group A TB drug (the most potent second-line drugs,
and include levofloxacin, bedaquiline, linezolid, and moxifloxacin).5 PreInfection and Drug Resistance 2021:14 5429–5448
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extensively drug-resistant TB (pre-XDR-TB) is defined as
resistance to isoniazid and rifampin, as well as any
fluoroquinolones.5
Drug-susceptible TB (DS-TB) is tuberculosis that is
susceptible to all forms of standard treatment, and is
normally treated with isoniazid, rifampin, pyrazinamide,
and ethambutol.6,7 Compared to patients with DS-TB,
patients with drug-resistant strains of TB have consider
ably longer treatment regimens (regimens can be as long
as 18–24 months for resistant strains compared to the
standard 6-month regimen for non-resistant strains in
DS-TB patients) which are more costly (treatment for
XDR-TB can cost more than 25 times that of standard
treatment [$494,000 USD compared to $17,000 USD]8),
and the negative side-effects of the drugs are more severe.
Due to the difficulties associated with treatment, patients
with DR-TB have higher default rates for treatment com
pared to those with DS-TB.9,10
Concerns about drug-resistant infections have been on
the rise in recent years, with TB cases resistant to all
available forms of treatment among the most worrisome.
The first reported cases were described in Italy and
Germany in 2007.11 Additional reports of cases came
from Iran in 2009, followed by India in 2012, and South
Africa in 2013.12–14 Since the emergence of these initial
cases, it is not clearly understood how many more cases,
which are resistant to all forms of treatment, have
emerged.
Cases that have been identified as XDR-TB comprise
an estimated 5.4% of all cases of DR-TB, or approxi
mately 0.3% (5.1 million) of all global cases of TB.15
However, cases of XDR-TB may be greatly underesti
mated because some patients may receive care in the
private sector and because many individuals living in
under-resourced settings never receive a diagnosis or
treatment.16,17
The outlook for new antimicrobial drugs against XDRTB is grim. Despite the urgent need, only minimal, new
classes of antibiotics have been created in recent years.
Antibiotics, such as those needed to treat TB, have a very
low economic return, and so pharmaceutical companies
devote only limited amounts of resources to their
development.18 Moreover, there are sizeable additional
costs, along with other difficulties, associated with distri
buting drugs to regions experiencing XDR-TB. Lastly,
once XDR-TB becomes prevalent in an area, it holds the
potential to spread—as is the case with any drug-resistant
disease or infection—with catastrophic consequences.19–21
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XDR-TB incidence has been rising in recent years.22
Furthermore, it has been demonstrated that XDR-TB
patients have poorer outcomes (death/treatment default/
failure) at rates much higher than those of non-XDR-TB
patients.23 Considering the extent of this issue, controlling
XDR-TB is a very important global health priority. To
better address this global health issue, more information
is needed about the risk factors for poor outcomes asso
ciated with this infection. A review on the risk factors for
XDR-TB that analyzed the literature published from 2006
to 2010 found that risk factors for developing XDR-TB
included immigration status, HIV coinfection, alcoholism,
having previously been infected with TB, and having preXDR-TB;15 however, the authors noted that the literature
was quite limited and that a more thorough investigation
of possible risk factors is needed.15 While a recent sys
tematic review has focused on the risk factors for poor
outcomes among DR-TB, minimal detail was given
regarding risk factors specifically for XDR-TB.24
Therefore, the purpose of this scoping review was to
provide information on risk factors associated with poor
outcomes for patients with XDR-TB.

Methods
Two reviewers (KV and BA) independently searched
PubMed, Scopus and ProQuest, with the workflow follow
ing the “Preferred Items for Systematic Review and MetaAnalyses extension for Scoping Reviews” (PRISMA-ScR)
guidelines.25,26 All searches were conducted on July 10,
2020. As this review expands on a systematic review
conducted in 2014 by Flor de Lima and Tavares, which
analyzed risk factors for XDR-TB in studies published up
to June 2010,15 our searches were restricted to articles
published after June 2010.
The most highly resistant forms of TB have been
described in the literature in a number of different ways,
aside from XDR-TB. These include: total drug-resistant
TB,27,28 totally drug-resistant TB,11–14 (TDR-TB), super
extensively drug-resistant TB (SXDR-TB or super XDRTB),12,29 extra extensively drug-resistant TB (XXDRTB),11,30 pan-resistant TB,36,37 pan drug-resistant TB
(PDR-TB),30–33,38,39 untreatable TB,34,35,40 untreatable
drug-resistant TB,36,37 incurable TB,20,41 and incurable
drug-resistant TB.42,43 The term extremely drug-resistant
TB has also, in some cases, been given the same abbrevia
tion as extra extensively drug-resistant TB (XXDRTB),38,42 and, in others, the same as abbreviation as exten
sively drug-resistant TB (XDR-TB)39,40 In order to
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account for this variation in terminology, all of these terms
were included as search terms in our review. Additionally,
our search terms referred to population-level factors and
individual-level factors, as well as outcomes. Complete
search terms are listed in Table 1.
Eligible settings included any region in the world
where there have been recorded instances of XDR-TB.
For the review process, the two reviewers screened poten
tial articles for eligibility based on title, abstract, key
words, and date of publication. Duplicates were removed
and all remaining full-text articles were then assessed.
Data were extracted from each study if they satisfied the
following inclusion criteria: (1) had a longitudinal design,
(2) were originally published in English, (3) provided an
analysis of population-level and/or individual-level risk
factors, (4) provided stratified data for patients with poor
outcomes (death/default/failed treatment) despite initial
treatment, (6) described the prevalence of at least one of
the levels of resistance described in Table 1, and (7)
included at least 10 patients who ended up with poor
outcomes. There was no registered study protocol for this
review.
Data collection and extraction was conducted by utiliz
ing the process from Flor de Lima and Tavares15 as a

framework. From all included studies, we extracted data
on study characteristics, such as: country, data source,
study design, sampling method, proportion of XDR-TB
cases compared to total cases of TB, and the proportion
of patients with poor outcomes. Thereafter, we extracted
data on patient characteristics related to the outcome of
interest, including sex, age, comorbidities, history of TB,
and additional relevant factors identified in the individual
study. These additional factors included, but were not
limited to smoking status, race, adverse events during
treatment, and body mass index (BMI).
Study quality was assessed using the Joanna Briggs
Institute’s (JBI) critical appraisal tools.44 Study metrics
that were assessed included reliability of exposure mea
surement, strategies to deal with confounding factors,
validity of outcome measures, follow-up completion and
loss of follow-up, and appropriateness of statistical of
analyses. Following the approach taken in a number of
different reviews,45–47 the JBI tools were modified to
provide a total score based on the number of yes/no
responses on an eleven-item scale for cohort studies, and
ten-item scale for case-control studies, and were depicted
graphically thereafter. Quality assessment scores are
shown in Supplementary Tables 1 and 2.

Table 1 Search Terms by Category*
Population

OR

Individual

AND

Outcomes
“Extensively Drug-Resistant Tuberculosis”

“Risk Factors”[Mesh] OR “Sociological

“Biological Variation, Individual”[Mesh]

Factors”[Mesh] OR “Socioeconomic

OR “Genetics, Behavioral”[Mesh] OR

OR “Extremely Drug-Resistant

Factors”[Mesh] OR “Social
Determinants of Health”[Mesh] OR

“Health Risk Behaviors”[Mesh] OR
“Patient Compliance”[Mesh] OR

Tuberculosis” OR “Extensively DrugResistant Tuberculosis” OR “Extremely

“Epidemiologic Factors”[Mesh] OR

“Medication Adherence”[Mesh] OR “HIV

Drug-Resistant Tuberculosis” OR “Extra

“Biological Variation, Population”[Mesh]
OR “Genetics, Population”[Mesh]

Infections”[Mesh] OR “Emigration and
Immigration”[Mesh] OR “Poverty”[Mesh]

Extensively Drug-Resistant Tuberculosis”
OR “Super Extensively Drug-Resistant

OR “Guideline Adherence”[Mesh] OR

Tuberculosis” “Totally Drug-Resistant

“Disease Susceptibility”[Mesh] OR
“Coinfection”[Mesh]

Tuberculosis” OR “Total Drug-Resistant
Tuberculosis” OR “Pan-Resistant
Tuberculosis” OR “Pan Drug-Resistant
Tuberculosis” OR “Pan Drug Resistant
Tuberculosis” OR “Untreatable
Tuberculosis” OR “Untreatable DrugResistant Tuberculosis” OR “Incurable
Tuberculosis” OR “Incurable DrugResistant Tuberculosis” OR “XDRTB” OR
“TDRTB” OR “XDR TB” OR “XXDR TB”
OR “TDR TB” OR “XDR-TB” OR
“XXDR-TB” OR “SXDR TB” OR
“PDRTB” OR “PDR TB” OR “SXDR-TB”
“SXDR TB” OR “SXDRTB”

Notes: *Mesh term used for PubMed, and its equivalent used for Scopus and ProQuest.
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analyses,46–50,62,63,68–70 and one was a case-control study.55
Twelve studies focused only on XDR-TB patients,49,50,54,60,62–
67,70,71
whereas the other 13 also included MDR-TB patients.
48,51–53,61,68,69,72
Total number of patients ranged from
67–3270. The proportion of patients with poor outcomes
ranged from 8.6%-88.7% across the studies.
Quality assessment scores are shown in Figure 2. Out
of 11 points total, the average score across cohort studies
was 8.0 (range 6–10). The score for the single case-control
study was 8 out of 10. The most frequent study limitations
were insufficient follow-up time, a lack of strategies to
describe and address incomplete follow-up, and a lack of
appropriate statistical analyses.
All of the articles described used the term exten
sively drug-resistant TB, and its associated abbrevia
tions. Two of the articles also utilized other terms and
abbreviations to describe the highest levels of resistance
in the patient population.57,65 Pietersen et al used the

The initial searches produced 2825 articles. After removal
of duplicates, 2150 remained, 1922 of which were
excluded after screening by title and abstract. Of the 228
articles that remained, 25 articles48–72 met eligibility
requirements and were included in the final review. The
complete workflow is listed in Figure 1.
The study characteristics for the 25 articles that were
reviewed are described in Table 2. The 25 articles provided
data from 11 countries. One article provided data from four
countries,48 whereas the other 24 articles each provided data
from a single country only. Twelve articles focused on South
Africa,53,55,56,60,62–67,70,71 four focused on China,50,61,69,72 four
on Latvia,48,59 four on Estonia,48,52 four on Russia,49,68 and one
on each of the following countries: India,57 Pakistan,58
Brazil,51 Lithuania,48 Romania,48 and Georgia.5454
Of the articles included, 16 were retrospective cohort
analyses,49–52,54–61,64–67 eight were prospective cohort

Figure 1 Study selection flow diagram.
Notes: PRISMAfigureadaptedfromPage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for
reporting systematic reviews. BMJ 2021;372:n71.CreativeCommons.26
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XDR-TB patients in 4 TB care centers across China (Changsha Central Hospital, Wuhan Treatment
Center, the Third People’s Hospital of Hengyang, and the Second People’s Hospital of Chenzhou)
MDR and XDR-TB patients in Rio de Janeiro; data from Tuberculosis Surveillance System

Tuberculosis patients across Estonia via the Tuberculosis Registry Database

Laboratory confirmed DR-TB patients of patients 18 years old and above across Eastern Cape
Province; data from Electronic DR-TB Register (EDRWeb) by the South African National TB
Programme
XDR-TB patients across Georgia; data from National TB program, medical charts, interviews, and
national Georgian death registry
MDR and XDR-TB patients in from the district hospital Tugela Ferry, KwaZulu-Natal; data from
medical records
MDR and XDR-TB patients in Tugela Ferry, South Africa; data came from medical records

MDR and XDR-TB suspected patients in a tertiary care hospital in Vellore, Tamil Nadu; data came
from medical records
MDR and XDR-TB patients who received care the MDR-TB unit in Peshawar, Khyber Pakhtunkhwa
province

China

Brazil

Estonia

South Africa

Georgia

South Africa

South Africa

India

Pakistan

Latvia

Bei et al
(2018)50

Bhering,
Duarte and
Kritski
(2019)51

Blöndal et al
(2012)52

Chingonzoh
et al (2018)53

Frank et al
(2019)54

Gandhi et al
(2012)55

Gandhi et al
(2010b)56

James et al
(2011)57

Javaid et al
(2018)58

Kuksa et al
(2014)59
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MDR and XDR-TB patients across Latvia; data from national TB registry

Two separate cohorts from Samara with data from TB patients’ register, and chart reviews (only the
second cohort was included for this review):
1)Non MDR-TB and MDR-TB patients in a pilot DOTS-programme, from the civilian and prison
sectors
2)XDR-TB patients, all of whom were civilians

Russia

Balabanova
et al (2011)49

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Case-control
study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Prospective
cohort study

Prospective
cohort study

564/1779 (31.7%)

129/535 (24.1%)*

21/177 cases (11.9%)

498/639 (77.9%)

189/262 (72.1%)

71/111 (67.0%)

1445/3729 (38.8%)

82/211 (38.9%)

1005/2269 (44.3%)*

20/67 (29.9%)

53/92 (57.6%)

227/737 (30.8%)*

Prospective
cohort study

MDR and XDR TB patients at Lung Hospital at Tartu University (Estonia), National Tuberculosis
and Infectious Diseases University Hospital in Vilnius (Lithuania), Clinic of Tuberculosis and Lung
Diseases at Riga East University hospital (Riga, Latvia), and Marius Nasta Institute of Pneumology
(Bucharest, Romania)

Latvia,
Lithuania,
Estonia,
Romania

Balabanova
et al (2016)48

Proportion of XDR
Patients with Poor
Outcomes (%)

Study
Design

Data Source

Country

Study

Table 2 Study, Region, and Participant Characteristics for Included Articles

133 (6.7%)

26 (4.9%)

45/177
(25.4%)

374 (58.5%)

139 (53.1%)

111 (100%)

763 (20.5%)

43 (20.4%)

140 (6.2%)

67 (100%)

92 (100%)

81 (11.0%)

XDR-TB
Patients (%
of Total)
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10/11

9/11

6/11

7/11

8/10

8/11

7/11

10/11

9/11

7/11

7/11

8/11

Quality
Score
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MDR and XDR-TB patients from the 309 hospital in Beijing

Chart records from XDR patients admitted to a public TB referral hospital in KwaZulu-Natal

Newly diagnosed adult XDR-TB patients in a public TB hospital in KwaZulu-Natal

Patients with laboratory-confirmed XDR-TB admitted to the Brooklyn Chest Hospital in Cape
Town, Western Province

Case records of XDR-TB patients at two TB facilities in Western and Northern Cape Provinces

Case records of laboratory-confirmed XDR-TB patients across three XDR-TB treatment centers
located in Gauteng, Northern Cape, and Western Cape
Patients who began MDR-TB treatment at the Tomsk Oblast TB Treatment Services facility in
Russia’s Western Siberia

China

South Africa

South Africa

South Africa

South Africa

South Africa

South Africa

Russia

China

Liu et al
(2011)61

O’Donnell et al
(2013)62

O’Donnell et al
(2015)63

Olayanju et al
(2018)64

Pietersen et al
(2014)65

Pietersen et al
(2015)66

Shean et al
(2013)67

Shin et al
(2010)68

Tang et al
(2013)69

Adult XDR-TB patients at a TB referral hospital in KwaZulu-Natal, South Africa

MDR-TB and XDR-TB patients from six regions in Zhejiang province: Hangzhou, Huzhou, Jiaxing,
Lishui, Quzhou, and Shaoxing

South Africa

China

Yuengling et al
(2018)71

Zhang et al
(2018)72

Prospective
cohort study

Prospective
cohort study

Prospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Prospective
cohort study

Prospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Retrospective
cohort study

Study
Design

148/537 (27.6%)*

72/105 (68.6%)

86/97 (88.7%)

346/1662 (20.8%)*

210/608 (34.5%)

55/115 (47.8%)

93/178 (52.2%)

93/107 (86.9%)

168/272 (61.8%)

49/216 (22.7%)

89/114 (78.1%)

280/576 (48.6%)

95/206 (46.1%)

Proportion of XDR
Patients with Poor
Outcomes (%)

Notes: *Presented as MDR and XDR-TB patients with poor outcomes/Total MDR and XDR-TB patients if stratification for XDR-TB patients’ poor outcomes was not conducted in study.

Patients with an XDR-TB diagnosis at the Brooklyn Chest Hospital in Cape Town

South Africa

Te Riele et al
(2019)70

MDR and XDR-TB HIV-negative patients in 5 hospitals across China (Shanghai Pulmonary Hospital,
Guangzhou Chest Hospital, Hangzhou Red Cross Hospital, Tianjin Haihe Hospital and Henan
Infectious Hospital)

XDR-TB patients from 3 XDR tuberculosis facilities: Brooklyn Chest Hospital (Cape Town,
Western Cape), Gordonia Hospital (Upington, Northern Cape), Sizwe Tropical Diseases Hospital
(Johannesburg, Gauteng Province)

XDR-TB patients in hospitals of Eastern Cape Province, South Africa

South Africa

Kvasnovsky
et al (2011)60

Data Source

Country

Study

Table 2 (Continued).

19 (3.5%)

105 (100%)

97 (100%)

169 (10.2%)

34 (5.6%)

55 (100%)

178 (100%)

107 (100%)

272 (100%)

216 (100%)

114 (100%)

48 (8.3%)

206 (100%)

XDR-TB
Patients (%
of Total)

10/11

10/11

8/11

6/11

7/11

7/11

7/11

8/11

9/11

8/11

6/11

8/11

10/11

Quality
Score
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Figure 2 Quality assessment score by study with the Joanna Briggs Institute’s Tools.

term totally drug-resistant TB,65 and James et al used
TDR-TB and XXDR-TB.57
Table 3 lists the risk factors for poor outcomes among
patients in the included studies. A history of TB was
consistently found to increase risk of poor outcomes
among XDR-TB patients. In a number of the studies
reviewed, nearly all patients who had a poor outcome
had been undergoing retreatment for TB after having pre
viously failed treatment/defaulted treatment/been cured.
One study found that 90.5% of patients with poor out
comes were retreatment cases.69 A different study found
that 93.0% of patients with poor outcomes had a history of
TB.68 In another study, all 45 patients with XDR-TB/
TDR-TB had a reported history of TB.57
Evidence from a wide array of contexts showed that
the presence of HIV increases risk for poor outcomes, and
in the three studies with the highest proportions of this
comorbidity, 79.6%,62 82.7,56 and 82.9%55 of patients had
both poor outcomes and HIV. The studies with the highest
proportion of cases of HIV were from South Africa. The
few studies that completed stratification based on whether
patients were HIV-positive and were receiving antiretro
viral therapies (ARTs) consistently found that risk of death
was considerably higher among people with HIV who did
not receive ARTs compared to those who did.56,60,64,71
Aside from HIV, findings related to comorbidities were
limited. Eight of the 25 studies included an analysis of dis
eases/health issues other than HIV.49–51,54,58,61,69,70

Infection and Drug Resistance 2021:14

Comorbidities included in these studies were: diabetes,
51,54,61,69,70
hepatitis,54,61,89 chronic obstructive pulmonary dis
ease (COPD),61,69 abnormal liver function,61 low albumin,69
and hypertension.61 The total proportions of patients with
comorbidities in these studies were generally relatively low,
with the exception of two studies.54,69 In the first of these two
studies, 26.8% of patients with poor outcomes had hepatitis C
virus.54 In the second study, 30.3% of patients with poor out
comes had low albumin levels, and 18.8% had diabetes.69
Findings related to age were mixed, although the majority
of the studies that analyzed age as a potential risk factor
showed that individuals approximately 30–45 years of age
were at the highest risk for poor outcomes,48,53–56,58,59,61,70,71
or that differences among age groups were minimal.49,63–65,68
Studies that included patients under 18 years of age indicated
that young patients comprise a relatively low proportion of
patients with poor outcomes.48,58,59,61
In 15 of the 25 articles, men were more likely than
women to be at risk for mortality, default, and/or treatment
failure.48–52,54,59–61,64,65,69–72 Some studies varied greatly
in the number of men and women included, with several
studies having a considerably higher proportion of male
participants with poor outcomes,48,54,59,61,72 and others
having considerably higher women.54,56,58,62
The studies identified a number of other risk factors.
Alcohol abuse was described in three studies;54,59,68 and
two of these studies each included individuals who were
regular consumers of alcohol and had TB with poor

https://doi.org/10.2147/IDR.S339972
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227/737 (30.8%)*

53/92 (57.6%)

20/67 (29.9%)

Estonia/
Tartu,
Lithuania/
Vilnius,
Latvia/Riga,
Romania/
Bucharest

Russia/
Samara

China/
Chuzhishi,
Wuhan,
Hengyan,
Chenzhou

Balabanova
et al
(2016)48

Balabanova
et al
(2011)49

Bei et al
(2018)50

XDR-TB Patients with PO/Total
XDR-TB Patients* (%)

Country/
City

Study

https://doi.org/10.2147/IDR.S339972

Exact numbers not
specified
aHR for male sex
(univariable analysis):
1.32, 95% CI: 0.44–
3.96

Exact numbers not
specified
Female HR in
comparison to males:
0.67, 95% CI: 0.37–
1.22

195/32

Males/Females

Table 3 Characteristics of Patients with XDR-TB and Having Poor Outcomes

Exact numbers
not specified
aHR for age>50
years: 2.40, 95%
CI: 0.84–6.85

Exact numbers
not specified
Greater than
40 years HR in
comparison to
those 40 and
below: 1.01,
95% CI: 0.98–
1.03

15–29: 13
30–39: 37
40–49: 62
50–59: 72
60+: 43

Ages in Years
(Range)

Cases combined with underlying
diseases (exact numbers not specified)
aHR: 3.48, 95% CI: 1.30–9.36

Exact numbers not specified
HIV-positive HR in comparison to HIVnegative: 1.23, 95% CI: 0.49–3.11
Median survival time for HIV-positive
patients was 185 days, compared to 496
days for HIV-negative patients

HIV-positive: 10
Condition other than HIV: 22

Comorbidities

Exact numbers not
specified:
aHR for retreatment cases
(univariable analysis): 0.43,
95% CI: 0.17–1.08

Exact numbers not specified
Treatment history HR in
comparison new patients:
1.54, 95% CI: 0.37–6.34

Retreatment case: 148
92 had an unsuccessful
treatment outcome in the
past
56 had a successful
treatment outcome in the
past

History of TB

aHR for patients with BMI < 18.5
kg/m2: 4.52, 95% CI: 1.31–15.65
aHR for patients with smoking
history: 4.67, 95% CI: 1.66–3.16

149 resided in an urban setting
78 resided in a rural setting
173 were unemployed
152 were smokers
212 had only pulmonary (ie non
extrapulmonary) TB
28 were smear positive at
diagnosis
31 were not smear positive at
diagnosis
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71/111 (67.0%)

463/763 (60.7%)

South Africa/
Eastern Cape
Province
(city not
specified)

Chingonzoh
et al
(2018)53

Georgia (no
particular
city)

20/43 (46.5%)

Estonia (no
particular
city)

Blöndal et al
(2012)52

Frank et al
(2019)54

1005/2269 (44.3%) *

Brazil/Rio de
Janeiro (no
particular
city)

Bhering,
Duarte and
Kritski
(2019)51

56/15

218/245

Exact numbers not
specified.
Male aHR: 3.61, 95%
CI: 1.42–9.15

Exact numbers not
specified
Male univariable
analysis aOR: 1.11
95% CI: 0.93–1.23
Male multivariable
analysis aOR (for
default only): 1.42,
95% CI: 1.08–1.87

Exact numbers
not specified
Median age:
39.0, IQR:
29.8–51.9

18–29: 125
30–44: 224
45–59: 103
60+: 11
Median (IQR):
36 (29–44)

Not specified.

Exact numbers
not specified
40+
multivariable
analysis aOR:
1.32, 95% CI:
1.06–1.66

Hepatitis C Virus: 19
HIV-positive: 2
Diabetes mellitus: 6

HIV-positive: 324
HIV-positive and on ART treatment: 318
Compared to those who were HIVnegative, those coinfected with HIV and
on ART had an aIRR of 1.1, 95% CI: 1.0–
1.3, and those coinfected with HIV and
not on ART had an aIRR of 1.8, 95% CI:
1.5–2.2

Not specified.

Exact numbers not specified
HIV positive multivariable analysis aOR:
1.60, 95% CI: 1.05–2.43
Diabetes multivariable analysis aOR:
0.72, 95% CI: 0.53–0.98
Other comorbidities multivariable
analysis aOR (for default only): 0.39,
95% CI: 0.22–0.67
Other comorbidities multivariable
analysis aOR (for death only): 2.03, 95%
CI: 1.36–3.01

41

History of TB with 1st line
drugs as treatment: 194
History of TB with 2nd line
drugs as treatment: 209

Exact numbers not
specified.
History of previous antituberculosis treatment aHR:
3.96, 95% CI: 1.94–8.07

Exact numbers not specified
Previous MDR-TB
treatment multivariable
analysis aOR: 2.35, 95% CI:
1.79–3.09
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38 patients with poor outcomes
had reported tobacco use (OR
for PO: 4.75, 95% CI 1.83–12.31)
32 patients with poor outcomes
had reported alcohol use (OR for
PO: 2.29, 95% CI: 0.95–5.49)
31 patients with poor outcomes
had a history of incarceration
(OR for poor outcomes: 8.27,
95% CI: 2.32–29.52)

376 initiated treatment at a DRTB hospital
62 initiated treatment at a
community level site

Birth outside of Estonia aHR:
1.91, 95% CI: 1.03–3.53
Second line drugs not stopped
due to side effects aHR: 0.38, 95%
CI: 0.16–0.90

XDR-TB patients with poor
outcomes multivariable analysis
aOR (in comparison to MDR-TB
patients): 4.71, 95% CI: 2.67–8.33
Afro-Brazilian patients with poor
outcomes multivariable analysis
aOR: 1.33, 95% CI: 1.05–1.67
Drug using patients with poor
outcomes multivariable analysis
aOR: 1.78, 95% CI: 1.15–2.75
Smoking patients with poor
outcomes multivariable analysis
aOR (default only): 1.66, 95% CI:
1.06–2.61
Individualized treatment regimen
with poor outcomes (compared
to standard regimen) univariable
analysis aOR: 1.56, 95% CI: 1.31–
1.86
Unemployed patients with poor
outcomes univariable analysis
aOR: 1.60, 95% CI: 1.28–2.00
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Not specified for XDR TB patients;
21/177 cases reported as resistant to
all forms of available treatment
(reported as XXDR-TB and TDR-TB
– though these 2 terms were used
interchangeably)

India/Vellore

James et al
(2011)57

129/535 (24.1%)*

310/374 (83%). Medical records only
available for 139 XDR-TB patients

South Africa/
Tugela Ferry

Gandhi et al
(2010b)56

Pakistan/
Peshawar

111/139 (79.9%)

South Africa/
Tugela Ferry

Gandhi et al
(2012)55

Javaid et al
(2018)58

XDR-TB Patients with PO/Total
XDR-TB Patients* (%)

Country/
City

Study

Table 3 (Continued).

62/67

Exact numbers not
specified

61/78

54/57

Males/Females

<18: 15
18–40: 69
41–60: 30
60+: 15

Exact numbers
not specified

Median (IQR):
34 (29–42)

Exact numbers
not specified
Median (IQR):
35 (29–43)

Ages in Years
(Range)

Comorbidities (any): 6

Out of 86 consenting to test for HIV, 0
had the virus

HIV-positive: 115
Receiving ARTs at time of TB diagnosis:
25 (22% of HIV positive)

HIV-positive: 92

Comorbidities

History of TB: 120
Previous use of second line
drugs: 28

All (45; 100%) cases of
XDR-TB and TDR TB had
history of anti-TB drug use
12 (57.1%) of TDR TB cases
had previously used secondline drugs.
Mean duration of past antiTB treatment for TDR TB
cases (months): Mean:
25.38, SD: 25.73; p=0.770)
TDR-TB cases had been
given a mean of 4.10, SD:
3.87, p = 0.185 treatment
regimens in the past

Any previous TB treatment:
96 (69%)
Previous TB treatment in
the prior year: 78 (56%)

Previous TB treatment
(any): 82

History of TB

108 patients resided in a rural
area
106 patients were married
17 patients were unemployed
23 patients were housewives

Smoking history was more
common among those with nonresistant TB (40.0%) compared to
those with DR TB (27.0%), with
p=0.132

41 (30%) of XDR-TB patients had
a presence of extrapulmonary TB
Mortality was highest in the first
30 days after sputum collection.
Median survival time after sputum
collection for XDR-TB patients
was 28.5 days, 95% CI, 20–34; P <
0.0001.

73 had a positive sputum smear
(HR: 0.91, p=0.80)
20 (out of 92 HIV-positive) were
on ART (HR for those HIVpositive and on ART: 0.34,
p=0.009)
64 had been hospitalized within
the last year (HR: 2.04, p=0.002)
17 patients with <50 CD4 cells/
mm3 (compared to those with >
200 CD4 cells/m3, HR: 4.46,
p=0.01)
22 patients with 51–200 CD4
cells/mm3 (compared to those
with > 200 CD4 cells/m3, HR:
2.34, p=0.15)
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63/133 (47.4%)

86/206 (41.8%)

34/48 (70.8%)

Latvia (no
particular
city)

South Africa/
Eastern Cape
Province
(city not
specified)

China/Beijing

Kuksa et al
(2014)59

Kvasnovsky
et al
(2011)60

Liu et al
(2011)61

Infection and Drug Resistance 2021:14
28/8

Exact numbers not
specified
Male aOR: 1.2, 95%
CI: 0.6–2.4
Comparison of HIV
negative patients
with HIV-positive
patients not on HIV
treatment: Male
aOR: 1.1, 95%: 0.5–
2.4

48/15

0–14: 1
15–29: 10
30–44: 13
45–59: 2
60–74: 6
75+: 2

Exact numbers
not specified
<25 vs 25–42
years aOR: 3.5,
95% CI: 1.3–9.6
<25 vs >42
years old aOR:
2.2, 95% CI:
0.8–6.5
Comparison of
HIV negative
patients with
HIV-positive
patients not on
HIV treatment:
<25 vs 25–42
years aOR: 3.6,
95% CI: 1.2–
10.3
<25 vs >42
years old aOR:
1.3, 95% CI:
0.4–3.8

< 18: 1
18–34: 18
35–54: 41
55+: 3

Diabetes mellitus: 1
COPD: 8
Abnormal liver function: 8
Hepatitis: 1
Hypertension: 4

Exact numbers not specified
HIV status aOR: 1.2, 95% CI: 0.5–2.6
Comparison of HIV negative patients
with HIV-positive patients not on HIV
treatment:
HIV status aOR: 2.5, 95% CI: 1.0–6.3

HIV-positive: 8

25

Exact numbers not specified
Previous MDR-TB episode
aOR: 1.3, 95% CI: 0.4–4.3
Comparison of HIV negative
patients with HIV-positive
patients not on HIV
treatment:
Previous MDRT TB episode
aOR: 2.3, 95% CI: 0.6–8.7

Retreatment after first
treatment regimen: 12
Previous failure/default on
MDR-TB treatment: 20
Relapse after MDR-TB
treatment: 10
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24 patients were migrants
31 patients with poor outcomes
were reported to have resistance
to more than 5 drugs
31 patients with poor outcomes
had 4 or more years of TB
disease
20 patients with poor outcomes
not receiving 3 or more drugs,
whereas only 2 survived (OR:
8.57, 95% CI: 1.65, 44.43)
28 patients with poor outcomes
had smear-positivity at onset,
whereas only 5 survived (OR:
6.72, 95% CI: 1.47, 30.76)

65 XDR-TB diagnosed patients
died before treatment
Smear positive at treatment start
aOR for patients with PO: 2.0,
95% CI: 1.0–4.1
Comparison of HIV negative
patients with HIV-positive
patients not on HIV treatment:
Smear positive at treatment start
aOR for patients with PO: 2.2,
95% CI: 1.0–5.0

36 patients with alcohol abuse
had PO: RR: 1.2, 95% CI: 0.9–1.4
46 patients that were smearpositive at the start of treatment
had poor outcomes (RR: 1.9, 95%
CI: 1.2–2.8)
23 patients with poor
outcomeswere ex-prisoners (RR:
2.0, 95% CI: 1.4–2.7)
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168/272 (61.8%)

93/107 (86.9%)

South Africa/
Cape Town

South Africa/
Cape Town,
Upington,
Johannesburg

Olayanju
et al
(2018)64

Pietersen
et al
(2014)65

93/178 (52.2%)

89/114 (78.1%)
note: stratified data only available for
49 patients who died

South Africa/
KwaZuluNatal

O’Donnell
et al
(2015)63

South Africa/
Northern
and Western
Cape
Provinces
(cities not
specified)

49/216 (22.7%)

South Africa/
KwaZuluNatal

O’Donnell
et al
(2013)62

Pietersen
et al
(2015)66

XDR-TB Patients with PO/Total
XDR-TB Patients* (%)

Country/
City

Study

Table 3 (Continued).

Not specified.

Exact numbers not
specified
Male HR: 1.48, 95%
CI: 0.58–3.78
Male HR among
those HIV-positive:
0.76, 95% CI: 0.21–
2.82

Exact numbers not
specified.
Male aHR: 1.08, 95%
CI: 0.76–1.52

22/27
Female aHR: 0.95,
95% CI: 0.51–1.77

16/33
Female aHR: 1.83,
95% CI: 0.96–3.49

Males/Females

Not specified

Exact numbers
not specified
Age at time of
diagnosis HR:
0.99, 95% CI:
0.95–1.04
Age at time of
diagnosis
among those
HIV-positive
HR: 0.95, 95%
CI: 0.89–1.01

Exact numbers
not specified.
Age HR: 1.00,
95% CI: 0.97,
1.03

<36: 25
36+: 24
<36 HR: 1.03,
95% CI: 0.59–
1.80

Exact numbers
not specified.
Age aHR (per
every 5 years):
1.18, 95% CI:
1.02–1.37

Ages in Years
(Range)

HIV-positive OR: 2.90, 95% CI: 1.34–
6.30

Exact numbers not specified
HIV infection HR: 1.48, 95% CI: 0.50–
4.39

Exact numbers not specified.
HIV-positive aHR: 1.51, 95 CI: 1.06–2.15
HIV-positive on ART aHR: 1.31, 95% CI:
0.44–2.91

HIV-positive: 36
HIV-positive aHR: 1.30, 95% CI: 0.61–
2.78

HIV-positive: 39
HIV-positive on ART: 24
HIV-positive aHR: 1.85, 95% CI: 0.65–
5.26

Comorbidities

Not specified

Exact numbers not specified
Net sputum culture
conversion ratio for those
with no history of MDR-TB
compared to those with a
history of MDR-TB: 10.21,
95% CI: 2.64–39.38
Among those with HIV, no
history of MDR-TB HR:
1.61, 95% CI: 0.37–6.96

Exact numbers not
specified.
History of TB treatment (all
patients) aHR: 1.08, 95% CI:
0.69–1.68
History of TB treatment
(HIV-positive patients) aHR:
1.29, 95% CI: 0.65–2.54

History of TB treatment: 38
History of TB treatment
aHR: 1.28, 95% CI: 0.45–
3.65

History of TB treatment: 46
Does not have a history of
TB treatment aHR: 0.97,
95% CI: 0.23–4.03

History of TB

Weight (kg) OR: 0.935, 95% CI:
0.902–0.969
Capreomycin rrs resistance
(A1401G mutation) OR: 0.59,
95% CI: 0.21–1.65
Provision of Co-amoxicillin/
clavulanic acid as treatment OR:
3.1, 95% CI: 1.4–6.6

1 reported case of totally drugresistant tuberculosis
Increased resistance was
associated with Beijing genotype
of disease (OR: 2.66, 95% CI:
1.18–17.35)

Weight <50 kg aHR: 1.96, 95% CI:
1.38–2.78
Bedaquiline provided as
treatment aHR: 0.14, 95% CI:
0.06, 0.30
Any aminoglycosides provided as
treatment aHR: 4.10, 95% CI:
1.87, 8.97

Adverse event during treatment:
23
Adverse event during treatment
HR: 1.02, 95% CI: 0.58–1.79

Capreomycin provided as
treatment: 38.
Capreomycin provided as
treatment aHR: 1.68, 95% CI:
0.83–3.41
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55/115 (47.8%)

29/34 (85.3%)

346/1662 (20.8%)*

86/97 (88.7%)
note: stratified data only available for
64 patients

72/105 (68.6%)

South Africa/
Gauteng,
Northern
Cape,
Western
Cape (cities
not
specified)

Russia/
Tomsk

China/
Shanghai
Guangzhou,
Hangzhou,
Tianjin, and
Henan

South Africa/
Cape Town

South Africa/
KwaZuluNatal
Province
(city not
specified)

Shean et al
(2013)67

Shin et al
(2010)68

Tang et al
(2013)69

Infection and Drug Resistance 2021:14

Te Riele et al
(2019)70

Yuengling
et al
(2018)71

Exact numbers not
specified
Female aHR: 0.71,
95% CI: 0.38–1.34

40/24

225/121

Exact numbers not
specified.
Male sex aHR: 0.37,
95% CI: 0.17–0.81

Not specified

Exact numbers
not specified
<36 aHR: 0.72,
95% CI: 0.37–
1.38

Median (IQR):
35 (27–45)

<45: 151
(43.6%)
45–65: 131
(37.9%)
65+: 64 (18.5%)

Exact numbers
not specified.
Age aHR: 1.01,
95% CI: 0.17–
0.81

Not specified

HIV-positive: 46
HIV not on ART aHR (ref: HIV-negative):
4.68, 95% CI: 1.16–18.94
HIV on ART aHR (ref: HIV-negative):
1.59, 95% CI: 0.69–3.48

Diabetes mellitus: 5
HIV-positive: 31

Diabetes: 65
COPD: 37
Chronic hepatitis:
30
Tumor: 10
Hepatic dysfunction: 39
Low albumin: 105

Exact numbers not specified.
HIV-positive HR: 3.11, 95% CI: 0.43–
22.71

Not specified

Any TB history aHR: 4.76,
95% CI: 0.65–34.95
History of MDR-TB
treatment aHR (univariate
analysis): 1.21, 95% CI: 0.65–
2.24

History of DR TB: 38

Retreatment case: 313
Duration of previous antiTB treatment:
<1 year: 83
1+ year: 263

Exact numbers not
specified.
Prior TB treatment with a
second-line injectable aHR:
3.65, 95% CI: 1.81–7.37
Prior TB treatment with a
quinolone HR: 3.31, 95% CI:
1.61–6.79

Exact numbers not
specified.
History of MDR-TB aHR:
2.91, 95% CI: 1.16–7.35
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An analysis of factors associated
with favorable outcomes was
conducted, and no other variables
were found to be significantly
associated with favorable
outcomes

Median weight (kg) (IQR): 50
(44–58)

147/169 of XDR-TB patients had
PO (OR of poor outcomes for
XDR-TB patients: 13.37, 95% CI:
6.75–26.50)
172 had a BMI of <18.5
174 had a BMI of 18.5+ (OR for
poor outcomes: 2.19, 95% CI:
1.37–3.48)
77 (had the highest level of
education as primary school
204 had the highest level of
education as middle school
55 had the highest level of
education as undergraduate
120 were peasants
135 were workers
91 had some other occupation

Started in TB hospital HR: 2.28,
95% CI: 1.11–4.68
Alcohol use during treatment HR:
1.58, 95% CI: 0.80–3.11
Baseline bilateral and cavitary
lesions aHR: 3.47, 95% CI: 1.32–
9.14

Grade 3–5 adverse event aHR
(note: reference is Grade 0–2
adverse event):1.43, 95% CI:
0.67–3.05
6 month culture conversion aHR:
0.10, 95% CI: 0.01–0.747
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Notes: *Presented as MDR and XDR-TB patients with poor outcomes/Total MDR and XDR-TB patients as stratification for XDR-TB patients’ poor outcomes was not conducted in study.
Abbreviations: TB, tuberculosis; DR-TB, drug-resistant tuberculosis; MDR-TB, multi-drug resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis; pre-XDR-TB, pre-extensively drug-resistant tuberculosis; DS-TB, drugsusceptible tuberculosis; USD, United States dollar; HIV, human immunodeficiency virus; PRISMA-ScR, Preferred Items for Systematic Review and Meta-Analyses extension for Scoping Reviews; JBI, Joanna Briggs Institute; BMI, body mass
index; ARTs, anti-retroviral therapies; DOT, directly observed therapy; EDRWeb, Electronic Drug-Resistant Tuberculosis Register; COPD, chronic obstructive pulmonary disease; OR, odds ratio; HR, hazard ratio; CI, confidence interval;
aHR, adjusted hazard ratio; aOR, adjusted odds ratios; SD, standard deviation; kg, kilograms; IQR, interquartile range; ACF, active case finding; IPU, integrated practice units.

32 had individualized treatment
100 had standardized treatment
65 had adverse events during
treatment
90 had unknown level of baseline
resistance patterns
122 were not hospitalized prior
to treatment
92 were farmers
Relapse patients: 60
Treatment after failure/
default: 69
Other patients previously
treated: 7
Previously treated with 1st
line drugs only: 92
Previously treated with 2nd
line drugs: 50
Exact numbers not specified
<30: 21
30–60: 80
>60: 47
105/43
148/537 (27.6%)*
China/
Hangzhou,
Huzhou,
Jiaxing,
Lishui,
Quzhou, and
Shaoxing
Zhang et al
(2018)72

Males/Females
XDR-TB Patients with PO/Total
XDR-TB Patients* (%)
Country/
City
Study

Table 3 (Continued).

Ages in Years
(Range)

Comorbidities

History of TB

Additional Features

Varshney et al

outcomes.54,59 A history of smoking was reported in four
studies.50,51,54,57 In one of these studies, individuals with a
smoking history had an adjusted hazard ratio of 4.67 (95%
CI: 1.66–13.16) in comparison to those who had never
smoked.50 Another study had fairly similar results, with
smokers having an odds ratio (OR) for poor outcomes of
4.75 (95% CI: 1.83–12.31).54 Two studies analyzed history
of incarceration as a risk factor, and in both of these studies,
former prisoners had higher odds for poor outcomes com
pared to those who were not former prisoners.54,59 In one of
these studies, former prisoners had a relative risk of 2.0 (95%
CI: 1.4–2.7),59 and in the other study, former prisoners had an
OR of 8.27 (95% CI: 2.32–29.52).54 In two studies, low body
mass was associated with higher odds of poor outcomes.50,69
The adjusted hazards ratio for patients of a BMI less than
18.5 kg/m2 in a study involving 20 patients with poor out
comes was 4.52 (95% CI: 1.31–15.65),50 and the OR in
another was 2.19 (95% CI: 1.37–3.48).69
Although socioeconomic status was not directly ana
lyzed as a risk factor in any of the 25 studies reviewed,
several studies did analyze other measures related to socio
economic status. In one study, 76.2% were unemployed,48
and in another 13.2% were unemployed.58 A third study
showed that unemployed patients had 1.60 odds of poor
outcomes compared to those who were employed (95%
CI: 1.28–2.00).51 One study analyzed educational attain
ment and found that 22.2% of patients with poor outcomes
had primary school as their highest level of education and
59.2% with poor outcomes had middle school as their
highest level of education.69
Various other factors associated with poor outcomes
that emerged in individual studies included having extra
pulmonary TB,56 being a migrant,52,61 having a Beijing
genotype of disease,65 being treated with clavulanic acid,66
residing in a rural area,48,58 being of African descent,51
illicit drug-use,51 having had adverse reactions to TB
treatment,52,63,67,72 being a farmer,72 and initiating treat
ment at a hospital rather than a community-level site.53,68
Based on the limited evidence, it was not possible to
determine if these were risk factors XDR-TB.

Discussion
While at least 123 countries across the globe have reported
the existence of XDR-TB,80 the majority of the studies in
this review (16 of the 25 studies) were conducted either in
South Africa or China. Globally, approximately half of the
cases of MDR-TB occur in India, Russia, and China and
XDR-TB was reported to be prevalent in India as far back
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Dovepress

as in 2012.13,81 However, only one study from India,57 and
two from Russia49,68 were eligible for this review. It is
therefore strongly recommended that more studies be con
ducted in India and Russia on risk factors for poor out
comes of XDR-TB.
In our review, it was found that a number of different
factors have been shown to increase the risk for poor
outcomes among XDR-TB patients. These include a pre
vious history of TB, alcoholism, smoking, low BMI,
unemployment, as well as being male, formerly incarcer
ated, and middle-aged.
Our review has also shown that certain comorbidities
consistently increase the risk for poor outcomes by XDRTB. In particular, HIV appears to be a risk factor, espe
cially when untreated. These findings may explain why
many of the studies included in this review were from
South Africa, a country with the highest number of people
living with HIV in the world.79 It is also plausible that
socioeconomic status and quality of care served as con
founders in this relationship, though these factors were
infrequently analyzed in the studies included in this
review. A number of studies in this review also showed
evidence that diabetes is a risk factor for poor outcomes
among XDR-TB patients.51,54,61,69,70
There are notable similarities between the findings of
our review, and those of prior reviews on risk factors for
mortality from other forms of DR-TB, as well as DS-TB.
While previous reviews on DS-TB have had conflicting
findings,82,83 HIV with advanced immunosuppression,
non-infective comorbidities, alcohol use, and substance
misuse have been identified as possible risk factors for
mortality among DS-TB patients.82,83 Furthermore, similar
to our findings, a previous review by Alemu et al24 showed
that, among DR-TB patients, risk factors for mortality
included being male, having HIV, clinical complications,
and having diabetes or any other comorbidity.
Considering the risk for poor outcomes of coinfected
HIV-positive patients, regardless of the level of drug-resis
tance, there is a clear need to focus on increasing access to
care among this demographic. Settings that are endemic
with both TB and HIV will require scaling up of resources
to ensure that patients are treated for both diseases con
currently. As well, any type of comorbidity increases a TB
patient’s risk for poor outcomes at all levels of drugresistance, and this may be because TB both increases
risk for other comorbidities and complicates management
of pre-existing conditions.84 This further emphasizes the
importance of ongoing efforts, such as the World Health
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Organization’s End TB strategy, to focus on management
of comorbidities among TB patients.84 We hence recom
mend that future research be conducted on the possible
relationship between XDR-TB and HIV, as well as dia
betes and other comorbidities.
In contrast with previous reviews on risk factors for TB
mortality,24,82,83 our review showed that there is strong
evidence indicating that a previous history of TB is a
risk factor for poor outcomes. Notably, all 25 studies
reviewed included a proportion of individuals who pre
viously underwent treatment for TB and died as a result of
XDR-TB infection. While previous reviews on TB mor
tality have shown that, as age increases, risk for death also
increases,24,82,83 our review instead demonstrated that
those most commonly aged 30–45 were at a greater risk.
Former prisoners, smokers, those with low BMI, and those
with COPD were found to be at an elevated risk for poor
outcomes in our review, which was not shown to be the
case for patients with DS-TB/other forms of DR-TB in
previous reviews.24,82,83
As rates of poor outcomes among XDR-TB patients
were shown to be exceedingly high in a number of
included studies, it is important to consider the risk factors
for developing XDR-TB alongside risk factors for XDRTB poor outcomes. In their systematic review on factors
for developing XDR-TB, Flor de lima and Tavares15 found
that previous TB treatment, prior TB treatment length,
having had pre-XDR-TB in the past, being an immigrant,
alcoholism, HIV co-infection, and being male all served as
major risk factors. It was also found that XDR-TB was
less likely to occur in older individuals, and there was
limited evidence that being a prisoner, having had cancer,
or diabetes increased risk.15
Our findings show that there are numerous important
similarities between risk for developing XDR-TB, and for
having poor outcomes. Therefore, it is critical that health
interventions which focus on addressing outcomes for
XDR-TB patients also concurrently prioritize preventative
efforts against XDR-TB. The exceedingly high rates of
poor outcomes among XDR-TB patients further highlights
this importance.
The consistency of the finding that prior treatment of
TB contributes to risk of both to developing XDR-TB, and
to having poor outcomes with XDR-TB, highlights the
need for efforts to ensure that patients consistently adhere
to treatment. To date, efforts to improve adherence have
focused on directly observed therapy (DOT) and DOT
Plus for DR-TB. These programs are effective in ensuring
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that patients complete their treatment regimens, and they
need to be continued and potentially scaled up. However,
these programs may not be enough to reduce escalation of
XDR-TB.
In order to address issues of patient adherence to TB
treatment, an array of additional solutions is needed. More
health facilities that offer complete care, and are located
closer to the place of residents of patients, are needed.
Patients undergoing lengthy treatment regimens may also
require transportation to care facilities, or perhaps delivery
services. Though the evidence regarding the positive
impacts of home delivery of TB treatment is limited,85
home delivery for treatment of other diseases has been
shown to be impactful.86,87
Patients may need support so that they can cope with
the severe physical and psychological side effects from
drug regimens used to treat the most resistant strains of
TB.10,73,74 Mental health care, including counselling, ther
apy, and prescribing of appropriate psychiatric treatment,
can help patients deal with the treatment side-effects as
well as with issues related to a lack of social support.75,76
The usage of integrated practice units (IPUs), which
involve the usage of mental health services within TB
facilities in the form of counselling sessions, has been
shown to both improve mental health symptoms and
increase TB treatment adherence rates.88 Scaling up of
IPUs may therefore be an effective intervention for TB
patients.
Reducing costs to patients and removing financial con
straints for TB treatment is also critical to improving
adherence rates,75–78 as numerous studies in this review
have shown that individuals with low educational/socio
economic standing tend to have worse outcomes.48,51,58,69
Lowering catastrophic costs, which are high expenses due
to TB that exceed a certain threshold of total household
income,89 will be crucial. Active case finding (ACF), a
strategy utilizing approaches such as house-to-house out
reach to find TB patients before they show major signs of
illness,90 has shown promise as an intervention that can
lower transmission rates,90 improve health outcomes,90,91
and reduce catastrophic costs for TB patients.90,92 ACF
hence have the potential to serve as interventions that can
contribute to prevention efforts and reduce the likelihood
of poor outcomes by early detection, while also lowering
financial burdens for patients. Cash transfer and microfi
nance programs, which have been implemented to address
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numerous health issues, may also have a role in improving
TB outcomes for impoverished patients.93
While a number of the findings of our review are compar
able to the previously mentioned review on risk factors for
developing XDR-TB by Flor de Lima and Tavares,15 there
are also important differences that need to be emphasized. In
contrast to their findings, it is worth reiterating that this
review showed that comorbidities greatly increase one’s
risk for poor outcomes, as does smoking, low BMI, being
formerly incarcerated, and being immunocompromised. Our
review also emphasizes that adverse reactions to XDR-TB
drugs may increase one’s risk for poor outcomes after devel
oping XDR-TB, though more research is required. These
differing findings indicate that the aforementioned factors
may have a measurable impact on XDR-TB outcomes, but
not necessarily for developing XDR-TB. More research is
therefore needed to better understand the extent to which
certain factors have on influence on developing XDR-TB,
compared to an influence on patient outcomes.
Further investigation of the possible relationship
between smoking and poor outcomes is also needed, and
more explicit guidelines may be needed to advise DR-TB
patients against smoking. An additional notable finding
was that individuals who were most at risk of poor out
comes from XDR-TB were approximately 30–45 years of
age. A possible explanation of why TB was more deadly
for this relatively younger group, rather than for older
individuals, is that they may be more likely to participate
in risky behaviors and less likely to completely adhere to
the arduous treatment regimen, perhaps due to financial
constraints. It is worth further analyzing the role of age in
future research.
This review included 25 studies from an array of geo
graphic locations and cultural contexts, which increases the
robustness of the overall findings. A number of these studies
had relatively large sample sizes, with some incorporating
thousands of individuals, thereby also increasing the robust
ness of the findings. Overall, the findings of the review
provide avenues for future research and important insights
to guide the development of policies and clinical guidelines.
Among the limitations to this review are the inconsis
tencies and variations in the way the articles reported
results, making it difficult to compare the results of the
different studies. Large confidence intervals across numer
ous findings require the usage of caution when interpreting
results. There were also inherent limitations in terms of
determining temporality. It is not known whether the
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mutable factors had occurred before diagnosis of TB, or
simply before the patient died.

Conclusion
XDR-TB patients have a high risk for mortality overall. Our
review highlights a number of important risk factors for poor
outcomes including being a smoker, being a former prisoner,
being middle-aged, being coinfected with HIV, and having a
previous history of TB. These findings contribute to the
literature by further emphasizing the urgency of ensuring
that TB patients adhere to antimicrobial treatment until the
pathogen is completely cleared, particularly among high-risk
groups. As well, the findings indicate a need for future
research to better understand other possible risk factors
such as adverse events during treatment, specific comorbid
ities, and being an immigrant. In consideration of the enor
mity of the threat that XDR-TB poses, there is a very strong
need for action to be taken.
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